Nasdaq
$4.17▲ 0.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $15.9MShares out 3.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 4d agoPre-market26.10.21 20:006-KKey event#●●●#●●●#●●●
PSYENCE BIOMEDICAL LTD.Bullish
Psyence Biomedical has completed an additional investment of US$2,599,896 in PsyLabs following the achievement of key development milestones for its ibogaine program. This investment increases the company's stake in PsyLabs from approximately 41.13% to 43.37% and supports the advancement of its U.S. development program through a cGMP manufacturing agreement with Benuvia.…more
$4.17+0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 22:03SCHEDULE 13D/AOwnership
PSYENCE BIOMEDICAL LTD.
A Schedule 13D/A filing has been submitted regarding the directors and executive officers of Psyence Biomedical Ltd. The filing details the personal information, business addresses, and citizenship of key board members and executives, including Control Services Corp.…more
$4.17+0.24%vs prev closeView filingShare - 10.5Regular26.10.05 22:40SCHEDULE 13GOwnership
PSYENCE BIOMEDICAL LTD.
AdvisorShares Trust has filed a Schedule 13G regarding its significant ownership stake in PSYENCE BIOMEDICAL LTD. This filing officially discloses the investor's acquisition of shares in the company.…more
$4.17+0.24%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:00#●●●#●●●#●●●
Psyence BioMed Completes PsyLabs Investment Following Ibogaine Milestones…more
Psyence BioMed has completed its additional investment in PsyLabs after achieving key milestones, including regulatory readiness and a U.S. cGMP manufacturing agreement. While this advances the company's U.S. ibogaine development program, the project remains in the early stages without established clinical efficacy.…more
$4.17+0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Pre-market26.10.05 20:00
●●●●●●●● ●●●●● ●●●●●●
Psyence BioMed's subsidiary TIRC has entered into a manufacturing agreement with Benuvia to produce pharmaceutical-grade ibogaine in the United States. The partnership remains subject to regulatory approvals and DEA production quotas, meaning future progress depends on these external authorizations.…more
$4.17+0.24%vs prev close - 9.28Pre-market26.09.28 20:07
●●●●●●●● ●●●●● ●●●●●●
Psyence Biomedical's subsidiary TIRC has signed a binding term sheet with PsyLabs for exclusive U.S. licensing and distribution rights for pharmaceutical-grade ibogaine. The agreement remains subject to a definitive contract by November 2026 and requires further clinical and regulatory development.…more
$4.17+0.24%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report